Voice AI medical scribe and clinical assistant for healthcare providers
Suki is a voice-enabled AI clinical assistant that helps physicians dictate notes and automate documentation directly into electronic health records. Founded in 2017 by former Google and Flipkart executive Punit Soni, Suki competes with Abridge, Microsoft's Nuance DAX, and Ambience in the rapidly consolidating ambient-AI scribe category. In October 2024, the company raised a $70M Series D led by Hedosophia at a ~$500M valuation, bringing total funding to $168M.
Healthcare AI📍 Redwood City, CAFounded 2017
Current Valuation
$500M
as of 2024-Q4
PRIVATE
QL Price
$500M
0% vs last round
QuantLogix's current estimate for Suki, published 2026-10-07 — in line with the last disclosed round of $500M (2024-Q4).
Confidence
low
Basis
round anchored
What backs this price
Last disclosed round
$500M
2024-Q4
weight 0.29
How this price has held up
No round has priced for Suki since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-10-07 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Suki, 2026-10-07 (67b36a4569b73796).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Suki going public?
No. Suki is private and has not filed to go public. There is no S-1 on file.
What is Suki's valuation in 2026?
Suki is valued at $500M as of 2024-Q4, set by its Series D ($70M, Oct 2024). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Suki filed an S-1?
No public S-1 is on file for Suki.
Who are Suki's investors?
Suki's investors include Hedosophia, Venrock, March Capital, Flare Capital Partners, inHealth Ventures.
How much has Suki raised?
Suki has raised $168M in total, most recently a Series D of $70M in Oct 2024.
Is Suki publicly traded — can you buy Suki stock?
No. Suki is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Suki on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
No verified Hugging Face organization found for Suki — no attributable open-model footprint. Closed-weights labs are common; this is a distribution signal, not a capability judgment.
Checked huggingface.co as of 2026-10-04. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-29% vs 2026-08
Open roles
10
via greenhouse
Product-build share
70%
engineering, research, product, design
Trajectory
tightening
heavy product build — 70% of open roles are product-building functions (engineering/research/product) — 4 of 10 open roles are engineering.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Clinical Quality Associate - IIProduct Manager, GrowthSenior AI EngineerSenior Forward Deployed EngineerSenior SDET (Mobile-First Full Stack)Software Engineer II - Backend
Counted from Suki's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Founders & Key People
Punit Soni
Investors
Hedosophia · Venrock · March Capital · Flare Capital Partners · inHealth Ventures
Products
Suki Assistant (ambient AI medical scribe)
Suki Platform (clinical-voice SDK for EHR partners)
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2024-Q4. Refreshed quarterly.